The Covid-19 Pivot

Rapid evidence reviews with the PEER team

Christina Korownyk, MD CCFP
Mike Kolber, MSc MD CCFP
Adrienne Lindblad ACPR, PharmD
James McCormack, PharmD
Mike Allan, MD CCFP FCFP
<table>
<thead>
<tr>
<th></th>
<th>Masks</th>
<th>Drug Treatment</th>
<th>Clinical Factors</th>
<th>Testing</th>
<th>Miscellaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mask use in healthcare workers for prevention of infection</td>
<td>Hydroxychloroquine for treatment of COVID-19 illness</td>
<td>Clinical presentation and course of COVID-19 infection</td>
<td>PCR testing – how reliability is our test?</td>
<td>Are these medications risky (ACE/ARB &amp; NSAIDs)</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Mask use in community for prevention of infection</td>
<td>Remdesivir and other Antivirals for COVID-19 illness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Masks**

1. Mask use in healthcare workers for prevention of infection
2. Hydroxychloroquine for treatment of COVID-19 illness
3. Clinical presentation and course of COVID-19 infection
4. PCR testing – how reliability is our test?
5. Are these medications risky (ACE/ARB & NSAIDs)
6. Mask use in community for prevention of infection
7. Remdesivir and other Antivirals for COVID-19 illness
8. Asymptomatic: frequency & transmission risk
10. Virtual Assessment of Dyspnea
Disclosure of Financial Support

**Faculty/Speaker: Christina Korownyk**
- Co-Director for Evidence and CPD, Alberta College of Family Physicians (ACFP)
- Spoken at conferences sponsored by ACFP

**Faculty/Speaker: Mike Kolber**
- Received honoraria for presentations/work: Best Science Medicine, ACFP, BCCFP, Alberta Expert Drug Committee
- Co-founder of EMPRSS – Electronic Medical Procedure Reporting Systems Inc, a University of Alberta/TEC Edmonton spin-off company that evaluates the quality of procedures performed by health care professionals

**Faculty/Speaker: Adrienne Lindblad**
- Employee of ACFP
Disclosure of Financial Support

**Faculty/Speaker: James McCormack**

➢ No conflicts of interest to declare

**Faculty/Speaker: Mike Allan**

Salary from The College of Family Physicians of Canada, University of Alberta, Locum

Relationship with financial sponsors:

➢ Grants/Research Support: Alberta College of Family Physicians; Toward Optimized Practice, CIHR, PRIHS, ON LHIN Grant, St. Paul’s Hospital

➢ Honoraria: Alberta, Ontario, NFLD, PEI, BC College of Family Physicians; Multiple University CPD depts, miscellaneous conferences

➢ Other: 2 RCTs (public funded)
To claim Mainpro+ credits:

- Scroll through the chat window on YouTube or Facebook at the end of webinar
- Look for the survey link and click on it
- Complete the survey by **end of day Sunday** (May 10, 11:59 p.m. ET)
After this webinar presentation, the participant will be able to:

1. Describe the best available evidence for the diagnosis of COVID-19
2. Describe the best available evidence for the treatment of COVID-19
3. Describe the best available evidence to prevent the transmission of COVID-19
1. Mask use in healthcare workers for prevention of infection
2. Hydroxychloroquine for treatment of COVID-19 illness
3. Clinical presentation and course of COVID-19 infection
4. PCR testing – how reliability is our test?
5. Are these medications risky (ACE/ARB & NSAIDs)
6. Mask use in community for prevention of infection
7. Remdesivir and other Antivirals for COVID-19 illness
8. Asymptomatic: frequency & transmission risk
10. Virtual Assessment of Dyspnea
**Masks**

- Surgical masks and respirators (N95) appear similar in preventing viral infections, with slightly lower infection rates (~1-2%).
- Cloth masks are poorer than surgical (with ~2% RTI x 4 wks).
- No RCTs examined transmission to others or COVID-19.
- Masks just one-part PPE and transmission precautions.

**Drug Treatment**

- Without further evidence, hydroxychloroquine is not appropriate for patients with COVID-19 in primary care. A number of recent trials/studies show an increased risk of side effects and QT prolongation especially at higher doses.
- Cough, fever and dyspnea are the most common symptoms of COVID-19.
- Studies of clinical PCR sensitivity are limited and vary widely for many reasons. Even if test sensitivity ranged between 50-90%, patients with low pretest probability (example 10%) would have at worst a 5% false negative rate.

**Clinical Factors**

- At least 80% of cases are clinically mild, ~10% are hospitalized and 25% of admitted patients require intensive care.
- Mortality risk factors include long-term care residents, age >65, co-morbid illnesses, and COVID-19 associated cardiac injury.

**Testing**

- Mortality risk factors include long-term care residents, age >65, co-morbid illnesses, and COVID-19 associated cardiac injury.
- There is no reliable evidence that NSAIDs, ACE inhibitors or ARBs increase the risk of COVID-19 or affect disease severity/mortality from COVID-19.

**Miscellaneous**

- Cough, fever and dyspnea are the most common symptoms of COVID-19.
- Mortality risk factors include long-term care residents, age >65, co-morbid illnesses, and COVID-19 associated cardiac injury.

**Transmission of COVID-19 can occur in people who are currently asymptomatic (including those who will remain asymptomatic and those who are early and not symptomatic yet). Case reports suggest this occurs in 6-13% of cases, although modelling suggests this might be higher. ~50% of carriers are asymptomatic when an entire population is tested.

**Tools for Practice**

- **PEER**
- **The College of Family Physicians of Canada**
- **Le Collège des Médecins de Famille du Canada**

---

**Mask in the community**

- May reduce transmission of viral RTI (from 2 RCTs). If community risk was ~25% over 6 weeks, masks could decrease that to ~19%. No COVID-19 research, many studies examined others risk once someone was sick, and the overall certainty of evidence is low. Any mask use should be combined with social distancing and other preventive strategies.

**To date, no published RCTs have demonstrated benefit of treating COVID-19 patients with remdesivir, lopinavir–ritonavir or oseltamivir. One interim analysis of remdesivir suggests improved time to recovery. Full publication of studies and ongoing trials will help to answer this question.**

**Transmission of COVID-19 may occur in people who are currently asymptomatic (including those who will remain asymptomatic and those who are early and not symptomatic yet). Case reports suggest this occurs in 6-13% of cases, although modelling suggests this might be higher. ~50% of carriers are asymptomatic when an entire population is tested.**

---

**Unfortunately, no specific technique, including the Roth Score, reliably assures dyspneic patients are safe. No studies assessed dyspnea in COVID-19 patients. Clinicians are encouraged to use available tools (BMJ Virtual Assessment tool) and have patients assessed in person if any concerns.**
To claim Mainpro+ credits:

- Scroll through the chat window on YouTube or Facebook at the end of webinar
- Look for the survey link and click on it
- Complete the survey by end of day Sunday (May 10, 11:59 p.m. ET)
CFPC’s Live-Stream Clinical Webinar Series:

**Practical Talks for Family Docs**

Join us at 12:00 p.m. (ET) ~

**May 14, 2020:**

The COVID-19 Pivot: Optimizing care of the elderly and long-term care residents during the pandemic (French)

**May 21, 2020:**

The COVID-19 Pivot: Clinical approaches to the global pandemic from an international panel (English)

**May 28, 2020:**

The COVID-19 Pivot: Caring for vulnerable populations during the pandemic (English)

Visit cfpc.ca/clinicalwebinars